To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)

Exclusion Criteria

• •se of any investigational or non-registered product (drug or vaccine) other than the HRV vaccine within 30 days preceding the first dose of HRV vaccine, or planned use during the study period.
• •Chronic administration of immunosuppressants or other immune-modifying drugs since birth.
• •Planned administration/ administration of a vaccines not foreseen by the study protocol except for DTPw, HBV/Hib and OPV vaccines within 14 days before each dose of HRV vaccine and ending 14 days after.
• •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
• •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
• •Household contact with an immunosuppressed individual or pregnant women.
• •Previous confirmed occurrence of RV GE.